Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. neo-vascular glaucoma or rubeosis~   * definition of neo-vascular glaucoma: patient with iris neovascularization with intraocular pressure elevation (exceeding 21 mmHg)~  * definition of rubeosis: patient with iris neovascularization without intraocular pressure elevation (≤21 mmHg)~2. an available follow-up of 12 months~3. written informed consent~4. visual acuity of light perception or better.~Exclusion Criteria:~1. history or evidence of severe cardiac disease (e.g., NYHA functional class III or IV)~2. clinical or medical history of unstable angina, acute coronary syndrome, myocardial infarction or revascularization with 6 months~3. ventricular tachyarrhythmias requiring ongoing treatment~4. History or evidence clinically significant peripheral vascular disease, such as intermittent claudication or prior amputation~5. Clinically significant impaired renal or hepatic function~6. Stroke within 12 month before trial entry.~7. Known serious allergies to the fluorescein dye use in angiography~8. Known contraindications to the components of Lucentis® formulation.~Ocular concomitant conditions/ diseases~1. Active intraocular inflammation (grade trace or above) in either eye~2. Any active infection (e.g. conjunctivitis, keratitis, scleritis, uveitis, endophthalmitis) in either eye~3. History of uveitis in either eye~4. Treatment with anti-angiogenic drugs (pegaptanib sodium, anecortave acetate,bevacizumab, ranibizumab, etc.) or intravitreal corticosteroids in either eye within 4 months prior to inclusion~5. Angle block glaucoma~6. Phthisis~7. Intraocular Pressure \<10mmHg~Compliance/ Administrative~1. Previous participation in any clinical studies of investigational drugs (excluding vitamins and minerals) within 1 month (or a period corresponding to 5 half-lives of the investigational drug, whatever is longer) prior to inclusion~2. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant. including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they are using two birth control methods. The two methods can be a double barrier method or a barrier method plus a hormonal method. Adequate barrier methods of contraception include: diaphragm, condom (by the partner), intrauterine device (copper or hormonal), sponge or spermicide. Hormonal contraceptives include any marketed contraceptive agent that includes an estrogen and/or a progestational agent.~3. Pregnant or nursing (lactating) women~4. Inability to comply with study or follow-up procedures.~5. Any treatment with an investigational agent in the past 60 days for any condition.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lucentis (Ranibizumab) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).